Ataraxis AI

We are thrilled to announce that Ataraxis AI has raised a $20.4 million Series A round led by AIX Ventures, with participation from Peter Thiel (Thiel Bio, Founders Fund), Floating Point, Bertelsmann Investments, Giant Ventures, Obvious Ventures, and visionary angel investors from healthcare and AI—including Mario Schlosser, Ryan Fukushima, Mei Z., Amrit Saxena, and researchers from OpenAI & DeepMind. This?milestone comes just a few months after emerging from stealth and unveiling the groundbreaking results of our clinical validation study for Ataraxis Breast, the world's first clinically validated, AI-native prognostic and predictive platform for breast cancer. We're honored to share this announcement alongside an exclusive story in TechCrunch, which highlights Ataraxis as a frontier AI lab for precision medicine that develops and deploys cutting-edge products reshaping oncology: https://lnkd.in/eTyVmiPB A huge thank you to our employees, investors, patients, and physicians.

We are hiring for multiple AI, medical, and commercial roles at Ataraxis! We recently raised a $20.4 million Series A from top VC and angel investors (AIX Ventures, Peter Thiel, Obvious Ventures) and are quickly growing to help millions of cancer patients worldwide. If you want to be a part of the fastest-growing AI precision medicine company, please consider applying: All jobs: https://lnkd.in/e24iQDBf → VP of Medical Affairs: https://lnkd.in/egps3b6m → VP of Sales: https://lnkd.in/eXAN2xks → Oncology Specialist: https://lnkd.in/e85SVApw → AI Research Engineer: https://lnkd.in/eupG3ZJ6 → AI Research Scientist: https://lnkd.in/eCbEN6c7 → Full Stack Engineer: https://lnkd.in/e3e7gEkU

Our team, including our CEO Jan Witowski MD PhD, will attend the #JPM2025 conference talking about our AI-native tools for treatment selection. Contact us to schedule a meeting: https://lnkd.in/eZECa2Dc

Very informative poster presentation by Jan Witowski MD PhD at the 2024 San Antonio Breast Cancer Symposium. The clinical validation results of Ataraxis Breast--the first AI-native prognostic/predictive test for breast cancer patients are impressive. Looking forward to continuing our collaboration with Ataraxis AI on the validation and implementation of AI prognostic and predictive models at Northwell Cancer Institute. #SABCS24 #AI #Prediction #Prognosis #BreastCancer

We are at San Antonio Breast Cancer Symposium 2024 next week: Jan Witowski MD PhD will present results of the Ataraxis Breast validation study—for the first time in public. This 8,161-patient study showed that our multi-modal AI predicts breast recurrence and survival in all major breast cancer subtypes, and with greater accuracy compared to a standard-of-care genomic test. We will also display how our state-of-the-art AI foundation model for digital pathology, Kestrel, accurately characterizes cancer histology and automatically identifies biomarkers with clinical accuracy. Come meet us! #SABCS24

We are coming to NeurIPS! Ataraxis AI team will present results of our novel approach to training state-of-the-art foundation models for digital pathology. This cutting-edge research goes beyond simply scaling model and data size, and led us to develop Kestrel, the foundation model behind Ataraxis Breast. Come see us!

“The entire mission of our company is to start providing information and answers to questions where there was no alternative.” Today in Forbes, Alex Knapp covers our founding story, our first product, and our mission to create tests that predict patient outcomes and personalize treatments for at least 50% of the 26 million new cancer patients expected to be diagnosed globally by 2030.

Today, we are launching Ataraxis AI to fulfill the promise of precision medicine. At Ataraxis, we are pioneering a new era of AI-native diagnostic tests that answer questions about patient outcomes and treatment response with greater accuracy, faster turnaround times, and broader applicability than molecular tests. Our first product, Ataraxis Breast, is the world's first AI-native prognostic/predictive test for breast cancer. Validated in a study of 8,161 patients across 15 cohorts from seven countries, this landmark study demonstrated that Ataraxis Breast: ?? Delivers up to 30% higher accuracy than standard-of-care molecular diagnostics ?? Works across all breast cancer subtypes, expanding testing to 100,000 more patients each year ?? Is faster, more cost-effective, and capable of addressing new clinical questions Ataraxis Breast is powered by Kestrel, our state-of-the-art AI foundation model for digital pathology. Kestrel is a pan-cancer model that provides new insights into cancer, enabling predictions for patient and treatment outcomes in breast cancer and beyond. Developed using the latest AI methodologies—including self-supervised learning and vision transformers—Kestrel was created with guidance from our special advisor, Yann LeCun. Last year, we raised $4M in a round co-led by Giant Ventures and Obvious Ventures. Thank you to our investors, team, and supporters. Learn more about today's announcement here: https://lnkd.in/embW5s7g. #AI #PrecisionMedicine #CancerDiagnostics #BreastCancer #CancerCare